02 Meningococcal McNamara 508

CDC ACIP — Vaccine Advisory Committee

Acip

Slides

7

Download PDF ↗ Live URL (may be dead)

Document text

Plan for revisiting the adolescent schedule 
for meningococcal vaccines
Lucy McNamara, PhD, MS
Interim Co -Lead, ACIP Meningococcal Vaccines Work Group
October 25, 2023National Center for Immunization & Respiratory Diseases
Considerations for routine schedule discussed 
during June 2023 ACIP meeting
▪Strong interest in revisiting the meningococcal vaccine schedule, including
–Whether 11 –12-year old dose is still needed given recent epidemiology 
–Revisiting SCDM for B vaccines
•Pentavalent vaccines may complicate the SCDM discussion for providers
•Nuances such as short duration of B protection may be lost in favor of 
giving a single injection
▪Opportunity to reduce number of vaccines (i.e., with pentavalent vaccines) is 
appealing if maintaining a high level of protection 
2
The Meningococcal Vaccines WG plans to 
revisit the schedule over the next year to 
ensure
▪Adequate time to perform GRADE and EtRassessments
▪Assessment of extended interval data for pentavalent vaccines
▪Integration of any changes into the overall child and adolescent 
immunization schedule 
▪Assessment of post -COVID epidemiology
3
Proposed key questions
▪Should the MenACWY series recommendations be changed to 
–Begin at an older age than currently recommended (11 –12 years)
–Eliminate the 11 –12 year -old dose or change this recommendation to 
SCDM?
▪Should the MenB series recommendations be changed to
–Alter the recommended ages or dosing interval to provide better 
protection for individuals aged 18 –19  years?
–Revisit the SCDM recommendation for some or all adolescents (e.g., 
those planning to attend college)?
▪Are there ways we can better integrate MenACWY and MenB vaccine 
schedules to streamline administration/increase feasibility?
4
Date Topics
Feb 2024 -Terms of reference for schedule change
June 2024-Epidemiology pertinent to possible schedule changes 
•Cases/deaths averted by MenACWY dose at 11 –12y 
•Meningococcal disease burden stratified by race/ethnicity in adolescents
•Risk factors for serogroup B meningococcal disease among college vs. non -
college students
•Breakthrough meningococcal disease cases in vaccinated individuals
•Extended interval data for pentavalent vaccines
Oct 2024 -GRADE/ EtRfor changes to MenACWY and MenB adolescent schedules
-CE analysis for changes to MenACWY and MenB adolescent schedules
Feb 2025 -VotesTentative timeline for ACIP meetings, 2024 –2025
5
Acknowledgments
▪ ACIP Members on the WG
– Kathy Poehling (Chair)
– Lynn Bahta
– Jamie Loehr
▪ Ex Officio WG Members
– Margaret Bash (FDA)
– Mark Connelly (FDA)
– Francisco Leyva (NIH)
▪ WG Liaisons and Consultants
– Amra Resic (AAFP)
– Samir Shah (AAP) 
– Sharon McMullen (ACHA)
– Cacky Tate / Karyn Lyons (AIM)
– Paul Cieslak (CSTE)
– Kathy Hsu (IDSA)
– Joseline Zafack (NACI)
– Jeff Goad (NFID)
– Jessica Cataldi (PIDS)
– Amy Middleman (SAHM)
– David Stephens (Emory)▪ CDC Contributors
– Jennifer Collins (DBD/NCIRD)
– Sam Crowe (DBD/NCIRD)
– Ismael Ortega -Sanchez (DVD/NCIRD)
– Andrew Leidner (ISD/NCIRD)
– LeAnne Fox (DBD/NCIRD)
– Susan Hariri (DBD/NCIRD)
– Amy Rubis (DBD/NCIRD)
– Noele Nelson (DBD/NCIRD)
– Alison Albert (DBD/NCIRD)
– Angela Jiles (DBD/NCIRD)
– Jonathan Duffy (DHQP/NCEZID)
– Tanya Myers (DHQP/NCEZID) 
– Liz Velazquez (ISD/NCIRD)
– Jessica MacNeil (ACIP Secretariat)
– Melinda Wharton (ACIP Secretariat)
▪ GRADE/EtR Support
– Doug Campos -Outcalt (Arizona)
– Rebecca Morgan (Case Western Reserve)
6
Thank you! 
Questions?